Clinical Trials Browser

Active not recruiting × Gemcitabine × Thoracic × Clear all

NCT06607185 2026-04-22

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Phase 1 Active not recruiting

GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT02194738 2026-04-21

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Phase NA Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05616624 2026-04-15

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT04216316 2026-04-13

Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

Phase 1/2 Active not recruiting

12 enrolled 25 charts

Lung Neoplasms

NCT04310007 2026-04-13

Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

Phase 2 Active not recruiting

Lung Neoplasms

NCT04491942 2026-04-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

Phase 1 Active not recruiting

BreastGenitourinaryGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Penile Neoplasms, Triple Negative Breast Neoplasms

NCT04083599 2026-04-08

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

Phase 1/2 Active not recruiting

DermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

Phase 2 Active not recruiting

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT03164616 2026-03-13

POSEIDON

Phase 3 Active not recruiting

1,186 enrolled 26 charts 2 FDA

Non Small Cell Lung Cancer NSCLC

NCT06704724 2026-03-13

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

Phase 1 Active not recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT03003962 2026-03-11

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

Phase 3 Active not recruiting

669 enrolled 54 charts

Non Small Cell Lung Carcinoma NSCLC

NCT03178552 2026-03-09

B-FAST

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02453282 2026-03-02

MYSTIC

Phase 3 Active not recruiting

1,118 enrolled 40 charts

Carcinoma, Non-Small-Cell Lung

NCT02422381 2026-02-18

MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Active not recruiting

16 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02542293 2026-02-12

NEPTUNE

Phase 3 Active not recruiting

953 enrolled 29 charts

Non Small Cell Lung Carcinoma NSCLC

NCT03819465 2026-02-11

MAGELLAN

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02486718 2026-02-05

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

Phase 3 Active not recruiting

1,280 enrolled 24 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT05867121 2026-02-02

A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010

Phase 1 Active not recruiting

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Stomach Neoplasms

NCT03456076 2026-01-30

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

Phase 3 Active not recruiting

257 enrolled 14 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT07005336 2026-01-30

A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05500092 2026-01-28

An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

Phase 2 Active not recruiting

Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

NCT03137771 2025-11-25

Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Phase 2 Active not recruiting

218 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung

NCT02495896 2025-11-10

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Gallbladder Neoplasms, Pancreatic Neoplasms

NCT03800134 2025-06-11

AEGEAN

Phase 3 Active not recruiting

825 enrolled 2 FDA

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT05096663 2025-05-15

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05919537 2025-04-18

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

Phase 1 Active not recruiting

GastrointestinalThoracic

Fibromatosis, Gingival, 2, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Pancreatic Neoplasms

NCT03425643 2024-12-03

MK-3475-671

Phase 3 Active not recruiting

797 enrolled 23 charts 2 FDA

Carcinoma, Non-Small-Cell Lung